Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET
Company Participants
Gail Cohen – Corporate Communications
Rick Winningham – Chief Executive Officer
Rhonda Farnum – Senior Vice President, Chief Business Officer
Rick Graham – Senior Vice President, Research and Development
Andrew Hindman – Chief Financial Officer
Conference Call Participants
Eva Privitera – Cowen
Operator
Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the Theravance Biopharma Second Quarter 2022 Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the Company’s formal remarks. [Operator Instructions] Also, today's conference call is being recorded.
And now I would like to turn the call over to Gail Cohen with Corporate Communications. Please go ahead.
Gail Cohen
Good afternoon, and thank you for joining the Theravance Biopharma second quarter 2022 conference call to discuss our business. As always, I remind you that this call will contain forward-looking statements that involve risks and uncertainties, including statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings and expected financial results.
Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in our filings with the SEC. I would direct your attention to Slide 3. Joining us are Rick Winningham, Chief Executive Officer; followed by Rhonda Farnum, Senior Vice President, Chief Business Officer; Rick Graham, Senior Vice President, Research and Development; and Andrew Hindman, Chief Financial Officer.
Now I will hand the call to Rick Winningham for opening remarks.
Rick Winningham
Thanks, Gail. Turning to Slide 4. Theravance Biopharma's purpose is to create medicines that make a difference. Last September, we announced a restructuring of the Company to optimize our business while staying true to our purpose. This quarter, the transformation continues. I couldn't be prouder of the team that's focused and persevere to deliver the strongest sales quarter for YUPELRI since its launch. Rhonda will review the performance details.
The successful Type C meeting for ampreloxetine, getting alignment with the FDA on a path to NDA filing with one additional Phase 3 study in multiple systems atrophy patients with symptomatic neurogenic orthostatic hypotension. Rick will give you an update as to where we are today. And the recently announced sale of our TRELEGY royalty interest to Royalty Pharma for approximately $1.1 billion in upfront cash and a total potential value of over $1.5 billion.